Stock OSL ONCOSIL MEDICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company OncoSil Medical Limited

Equities

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 01:06:22 2024-05-10 am EDT 		5-day change 1st Jan Change
0.004 AUD -11.11% Intraday chart for OncoSil Medical Limited -20.00% -55.56%
May. 02 OncoSil Medical Raises AU$5.3 Million under Entitlement Offer MT
Apr. 18 OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial MT

Business Summary

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

Sales per Business

AUD in Million2022Weight2023Weight Delta
Device Development for New Medical Treatment
100.0 %
0 100.0 % 0 100.0 % +58.63%

Sales per region

AUD in Million2022Weight2023Weight Delta
Australia and New Zealand
69.6 %
0 100.0 % 0 69.6 % +10.40%
Europe
30.4 %
-- 0 30.4 % -

Managers

Managers TitleAgeSince
Nigel Lange CEO
 Chief Executive Officer - 20-05-03
Christian Cin DFI
 Director of Finance/CFO - 23-05-31
Jon Bell CTO
 Chief Tech/Sci/R&D Officer - -
Henk Tissing CTO
 Chief Tech/Sci/R&D Officer - -
David Turner CTO
 Chief Tech/Sci/R&D Officer - 20-12-31

Members of the board

Members of the board TitleAgeSince
Nigel Lange CEO
 Chief Executive Officer - 20-05-03
Douglas Cubbin CHM
 Chairman - 23-08-06
Gabriel Liberatore BRD
 Director/Board Member - 23-07-13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,103,954,978 2,466,858,184 ( 79.47 %) 0 79.47 %

Shareholders

NameEquities%Valuation
Sarah Cameron
4.816 %
142,655,394 4.816 % 465 057 $
Titan Bioventures Management Pty Ltd.
0.3869 %
11,458,427 0.3869 % 37 354 $
Martin Cross
0.1523 %
4,510,965 0.1523 % 14 706 $

Company contact information

OncoSil Medical Ltd.

7 Eden Park Drive Level 5

2113, Macquarie Park

+

http://www.oncosil.com.au
address OncoSil Medical Limited(OSL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ONCOSIL MEDICAL LIMITED Stock OncoSil Medical Limited
-55.56% 7.94M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. OSL Stock
  4. Company OncoSil Medical Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW